Contrasting of Actinium Pharmaceuticals Inc. (ATNM) and Ardelyx Inc. (NASDAQ:ARDX)

We will be contrasting the differences between Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and Ardelyx Inc. (NASDAQ:ARDX) as far as profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actinium Pharmaceuticals Inc. N/A 0.00 N/A -0.20 0.00
Ardelyx Inc. 3 1212.63 N/A -1.68 0.00

Table 1 highlights Actinium Pharmaceuticals Inc. and Ardelyx Inc.’s top-line revenue, earnings per share and valuation.

Profitability

Table 2 provides the net margins, return on assets and return on equity of the two firms.

Net Margins Return on Equity Return on Assets
Actinium Pharmaceuticals Inc. 0.00% -213.7% -140.7%
Ardelyx Inc. 0.00% -78.4% -51.2%

Volatility & Risk

Actinium Pharmaceuticals Inc. has a 1.79 beta, while its volatility is 79.00% which is more volatile than Standard and Poor’s 500. Competitively, Ardelyx Inc. is 86.00% more volatile than Standard and Poor’s 500, because of the 1.86 beta.

Liquidity

Actinium Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 1.8 and 1.8 respectively. The Current Ratio and Quick Ratio of its competitor Ardelyx Inc. are 7.4 and 7.4 respectively. Ardelyx Inc. therefore has a better chance of paying off short and long-term obligations compared to Actinium Pharmaceuticals Inc.

Institutional & Insider Ownership

Actinium Pharmaceuticals Inc. and Ardelyx Inc. has shares owned by institutional investors as follows: 17.6% and 82.8%. Insiders owned 0.1% of Actinium Pharmaceuticals Inc. shares. Comparatively, 1.5% are Ardelyx Inc.’s share owned by insiders.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Actinium Pharmaceuticals Inc. -7.69% -4.98% -21.93% -58.43% -63.91% -39.84%
Ardelyx Inc. 1.69% -12.36% -26.97% 14.76% -38.99% 34.64%

For the past year Actinium Pharmaceuticals Inc. had bearish trend while Ardelyx Inc. had bullish trend.

Summary

Ardelyx Inc. beats Actinium Pharmaceuticals Inc. on 6 of the 7 factors.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Ardelyx, Inc. develops and sells therapeutics for the treatment of cardio renal and gastrointestinal diseases in the United States. Its lead product candidate is tenapanor, which is in Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. The company is also developing RDX7675, which is in Phase III clinical trial for the treatment of people with hyperkalemia; and RDX8940 in Phase I clinical trial for the treatment of patients with NASH and other gastrointestinal indications. Its drug candidates in the stages of research and development include RDX013 for the treatment of patients with hyperkalemia; RDX011 for the discovery and development of second-generation NHE3 inhibitors; and RDX023 for the discovery and development of gut-biased FXR agonists for the treatment of GI and inflammatory diseases. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.